Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Help Your Efficiency with These Work area Updates - 2Watch Chinese astronauts enjoy '1st ever space BBQ' from Tiangong's brand-new oven (video)
- 3What causes RFK Jr.’s strained and shaky voice? A neurologist explains this little-known disorder
- 4Interstellar comet 3I/ATLAS will fly by Earth Friday. Here are the latest images
- 5Every year, she thanks the trooper for the arrest that led to her sobriety
- Iran war fuels fears of new inflation wave among German consumers
- More loons are filling Maine's lakes with their ghostlike calls
- Earthquake in Indonesia kills at least 1 person and sets off small tsunami
- Must-See Attractions in Washington, D.C.
- Vote In favor of Your Favored Language Learning Applications
- New COVID-19 variant 'Cicada' is spreading. What to know about BA.3.2.
- Figure out How to Track and Anticipate Future Cd Rates
- Lucrative Positions in the Advancing Position Market of 2024
- Step by step instructions to Think about Disc Rates Across Various Banks
